NCT03275701View on ClinicalTrials.gov

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

NAUnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

November 30, 2019

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

Triumeq

Open Label, Switch to Triumeq (ABC/DTG/3TC)

Trial Locations (1)

90069

RECRUITING

Mills Clinical Research, Los Angeles

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Mills Clinical Research

INDUSTRY

NCT03275701 - Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC | Biotech Hunter | Biotech Hunter